Market Overview

UPDATE: Jefferies Raises PT on AbbVie on Attractive Valuation

Share:
Related
8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting
Gilead Responds To CMS Blog Highlighting High Cost Of Harvoni: Most Payers Receive Substantial Discounts Off The List Price
AbbVie's Imbruvica Has Favorable Response Rate Among Marginal Zone Lymphoma Patients (GuruFocus)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), and raised the price target from $45.00 to $50.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

AbbVie closed on Tuesday at $42.55.

Latest Ratings for ABBV

DateFirmActionFromTo
Nov 2016CitigroupDowngradesBuyNeutral
Oct 2016Credit SuisseDowngradesOutperformNeutral
Oct 2016Leerink SwannInitiates Coverage OnMarket Perform

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!